Clinical trials: Impulsivity
Cocaine Dependence
Vigabatrin for Treatment of Cocaine Dependence
The objective of this study is to demonstrate that a larger proportion of vigabatrin-treated subjects than placebo-treated subjects will be cocaine-free in the last 2 weeks of treatment.
- Trial name
- NCT00611130
- Testing
- vigabatrin
- Where
- 11 sites in United States
- Volunteers
- 186 people
- Sponsor
- Catalyst Pharmaceuticals, Inc.
Opioid Dependence
An Open Label Study To Assess The Safety And Tolerability Of BEMA® Buprenorphine NX In Opioid Dependent Subjects
This is an open label study in opioid dependent subjects maintained on a stabilized dose of Suboxone tablets or films. The purpose is to assess the safety and tolerability of BEMA Buprenorphine NX administered once daily for 12…
- Trial name
- NCT01666119
- Testing
- BEMA Buprenorphine NX films
- Where
- 10 sites in United States
- Volunteers
- 249 people
- Sponsor
- BioDelivery Sciences International
Attention Deficit Hyperactivity Disorder, ADHD
Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD
This multi-center parallel study is designed to study the efficacy and safety of fixed doses of methylphenidate extended release (ER) capsules of four dose levels compared with a placebo group in pediatric patients with Attention…
- Trial name
- NCT01239030
- Testing
- Methylphenidate Hydrochloride Extended Release Capsules
- Where
- 16 sites in United States
- Volunteers
- 230 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.
Substance Dependence
An Open Label Positron Emission Tomography (PET) Study of GSK618334 in Healthy Male Subjects Using 11C-PHNO as PET Ligand
The purpose of this study is to investigate the relationship between the plasma concentrations of the study drug and the amount of the study drug bound to the D3 receptors of the brain after dosing of a new compound GSK618334.
- Trial name
- NCT00814957
- Testing
- GSK618334
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Opiod Use Disorder
Safety, Tolerability, and Pharmacokinetics of Naltrexone Implant (DLP-160)
This is an Open-Label Study in Healthy Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics of Switching from Oral Naltrexone HCL to DLP-160 (Naltrexone implant) to Intramuscular Vivitrol®
- Trial name
- NCT05304364
- Testing
- Combination Product: Naltrexone
- Where
- Australia
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Delpor, Inc.
Impulsive Aggression Comorbid With ADHD in Children
Open-Label, Extension Study to 810P202
Open-label, extension study for subjects that completed 810P202 to examine long term safety and tolerability of repeated dosing of SPN-810M as an adjunctive therapy in children with Impulsive Aggression Comorbid with…
- Trial name
- NCT01416064
- Testing
- Molindone
- Where
- 28 sites in United States
- Volunteers
- 78 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Substance Dependence
GSK618334 Repeat Dose Study
The proposed study will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of repeated oral doses of GSK618334 in healthy male and female volunteers.
- Trial name
- NCT01036061
- Testing
- GSK618334 Low Dose, GSK618334 PET subjects, GSK618334 Medium Dose
- Where
- United Kingdom
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Attention Deficit Hyperactivity Disorder
Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder
This study tests the effects of an investigational antipsychotic drug (called OPC-34712) in adults with attention deficit hyperactivity disorder (ADHD) when taken with an approved stimulant medication to explore a possible impact…
- Trial name
- STEP-A (NCT01074294)
- Testing
- OPDC-34712, Stimulant Therapy
- Where
- 35 sites in United States
- Volunteers
- 740 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit/Hyperactivity Disorder (ADHD)
The Efficacy and Safety of Phosphatidylserine-Omega3 in Children With Attention-Deficit/ Hyperactivity Disorder
The primary objective of this trial is to determine whether an oral administration of Phosphatidylserine-Omega3 would significantly improve the clinical symptoms of children suffering from ADHD.
- Trial name
- NCT00418184
- Testing
- Phosphatidylserine-Omega3, Colored cellulose tainted with fishy odor
- Where
- Israel
- Volunteers
- 200 people
- Sponsor
- Enzymotec
Obsessive-Compulsive Behavior
rTMS Device for Improvement of Obsessive and Compulsive Behaviors
The goal of this investigational study is to evaluate if the treatment using EXOMIND(BTL-699-2) device is able to improve severity of obsessive and compulsive symptoms in adults (aged 22 and older).
- Trial name
- NCT07679750
- Testing
- EXOMIND (BTL-699-2) Active treatment
- Where
- 3 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- BTL Industries Ltd.
Addiction
A Study to Assess 18-Methoxycoronaridine (18-MC HCl) in Healthy Volunteers
The primary objective of this study is to assess the safety and tolerability of a single day dosing and a separate multiple day dosing of 18-MC HCl administered orally, each part of the study having a different set of healthy…
- Trial name
- NCT04292197
- Testing
- 18-MC Compound
- Where
- Australia
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Definium Therapeutics US, Inc.
Addictive Behavior, Alcohol Use Disorder
90-Day Online Substance Use Program
Individuals indicating risky substance use are randomly assigned either to a three-month online intervention on the Workit Health platform or a waitlist/treatment as usual.
- Conditions
- Addictive Behavior, Alcohol Use Disorder, Alcohol Abuse, Drug Abuse
- Trial name
- NCT03069118
- Testing
- Treatment - Workit Health Online Program, Control - Resource List
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Workit Health
Attention Deficit Hyperactivity Disorder (ADHD), Impulsive Aggression
Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHD
The purpose of this study was to evaluate the effect of 4-week SPN-810 treatment on brain functioning in patients aged 8-12 years with ADHD and associated feature of impulsive aggression (IA).
- Trial name
- NCT03638466
- Testing
- Functional Magnetic Resonance Imaging (fMRI), Magnetic Resonance Spectroscopy (MRS), Point Subtraction Aggression Paradigm (PSAP) Task
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Impulsive Aggression
Functional MRI Study in Healthy Children Engaged in Aggressive Behaviors
The purpose of this non-interventional study is to optimize the point subtraction aggression paradigms (PSAP) task in typically developing children (TDC).
- Trial name
- NCT03615703
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Supernus Pharmaceuticals, Inc.
Impulse Control Disorders, Borderline Personality Disorder
fMRI in Impulsivity
This study aims to use resting-state and task based functional Magnetic Resonance Imaging (fMRI) as a tool to evaluate trait characteristics of impulsivity in subjects with borderline personality disorder.
- Trial name
- NCT02755181
- Testing
- Experimental
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Alcohol Dependence
ALK21-018: Effects of Medisorb® Naltrexone (VIVITROL®) on Alcohol Craving in Treatment-seeking, Alcohol-dependent Adults
This was a study of the effects of VIVITROL® on alcohol cue-induced craving and the associated brain activation patterns in alcohol-dependent adults who had recently completed alcohol detoxification and were seeking further…
- Trial name
- NCT00511836
- Testing
- VIVITROL 380 mg
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Alkermes, Inc.
Attention Deficit Hyperactivity Disorder
A Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behaviour Problems in Children With ASD
The primary purpose of this study is to evaluate the tolerability and effectiveness of atomoxetine in the treatment of attention problems, hyperactivity, and impulsivity in children with ASD, and secondarily, to evaluate the…
- Trial name
- NCT00485849
- Testing
- Atomoxetine Hydrochloride
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Eli Lilly and Company
Opioid Use Disorder
A Stepped-Wedge Cluster Randomized Trial of a Digital App to Support Medication-Assisted Treatment in Individuals With Opioid Use Disorder
The goal of this clinical trial is to learn if a mobile health app called Recovery Connect can help people stay in treatment for opioid use disorder.
- Trial name
- SMART-OUD (NCT07140926)
- Testing
- Recovery Connect
- Where
- 9 sites in United States
- Volunteers
- 1,524 people
- Sponsor
- Bright Therapeutics
Patient Diagnosed With OCD and Resistant to SSRI Treatment, Failed SSRI Over 12 Weeks at Appropriate Doses
Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy
The purpose of this study is to determine whether AFQ056 as an add on therapy to SSRIs can have beneficial effects by reducing the total score of Y-BOCS (Yale and Brown Obsessive Compulsive Scale) in OCD patients resistant to…
- Trial name
- NCT01813019
- Testing
- AFQ056
- Where
- 15 sites in United States, Bulgaria and 3 more
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Substance Dependence
Effects of the D3 Antagonist GSK598809 on Food Reward and Reinforcement
This novel compound is a new experimental treatment that may help people to stop compulsive overeating. Compulsive overeating or binge eating is one of the main reasons why people are overweight or obese.
- Trial name
- NCT01039454
- Testing
- GSK598809 Capsules
- Where
- 2 sites in United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline